SHP647

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead
Endpoints
Fri, 05/29/20 - 10:45 am
Takeda
IBD
SHP647
Shire
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Sun, 10/28/18 - 07:47 pm
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647